GT Biopharma, Inc. (GTBP)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

6.80 on 12 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2020, ended 31 Dec 2020, as filed

Revenue

$0.00

Net income

$28.30M

Free cash flow

$7.26M

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
11 Apr 2023	Breen Michael Martin Executive Chairman/Interim CEO	Bought	$25.00K	8.2%
6 Apr 2023	Ohri Manu CFO & Secretary	Bought	$25.00K	opened
22 Dec 2020	Weldon Steven W Former Officer and Director	Sold, plan not stated	$19.19K	1.3%
22 Dec 2020	Wendel Bruce Director	Bought	$16.04K	55.5%
21 Dec 2020	Weldon Steven W Former Officer and Director	Sold, plan not stated	$43.65K	3.5%
18 Dec 2020	Weldon Steven W Former Officer and Director	Sold, plan not stated	$15.00K	1.3%

29out of 100

Profitability 25

Financial strength 17

Growth n/a

Insiders 50

Strongest on insiders (50), weakest on financial strength (17). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan